By Kelly Cloonan
Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders.
Under the agreement, Crispr will make an upfront payment of $25 million in cash and $70 million in equity to Sirius Therapeutics, the companies said Monday.
The companies will jointly develop SRSD107 under an equally split cost and profit-sharing structure, they said. Crispr will lead commercialization in the U.S., while Sirius will be responsible for commercialization in China.
Crispr will also be able to nominate up to two siRNA targets for research and development, for which it would retain opt-in rights to lead commercialization, the companies said. Sirius will be eligible to receive milestone payments as well as tiered royalties in high single to low-double digits.
SRSD107 aims to selectively inhibit Factor XI, a driver of pathological thrombosis, in order to reduce thrombotic events and minimize the risk of bleeding. Two Phase 1 trials of the treatment have found it to be safe and well-tolerated, the companies said.
The collaboration expands Crispr's portfolio to develop a broader range of gene-based medicines in addition to its gene-editing programs, the companies said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 19, 2025 16:44 ET (20:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.